Weekly oral bisphosphonates over 2 years prevent bone loss in cardiac transplant patients.

about

Weekly oral bisphosphonates over 2 years prevent bone loss in cardiac transplant patients.

Item

http://www.wikidata.org/entity/Q48053296

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Weekly oral bisphosphonates ov ...... n cardiac transplant patients.

@en

Weekly oral bisphosphonates ov ...... n cardiac transplant patients.

@nl

type

Item

label

Weekly oral bisphosphonates ov ...... n cardiac transplant patients.

@en

Weekly oral bisphosphonates ov ...... n cardiac transplant patients.

@nl

prefLabel

Weekly oral bisphosphonates ov ...... n cardiac transplant patients.

@en

Weekly oral bisphosphonates ov ...... n cardiac transplant patients.

@nl

P1476

Weekly oral bisphosphonates ov ...... n cardiac transplant patients.

@en

P2093

Katharina Classen

http://www.w3.org/2001/XMLSchema#string

Ulf Müller-Ladner

http://www.w3.org/2001/XMLSchema#string

Uwe Lange

http://www.w3.org/2001/XMLSchema#string

P2860

Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study.

Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group.

Osteoporosis after solid organ and bone marrow transplantation.

Management of bone loss after organ transplantation.

Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation.

Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation.

Vertebral fracture assessment using a semiquantitative technique.

Ibandronate prevents bone loss and reduces vertebral fracture risk in male cardiac transplant patients: a randomized double-blind, placebo-controlled trial.

Vitamin K2 inhibits glucocorticoid-induced bone loss partly by preventing the reduction of osteoprotegerin (OPG).

P31

scholarly article

P356

10.1111/CTR.13122

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Manfred Richter

P577

2017-09-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28940569

http://www.w3.org/2001/XMLSchema#string